starting compounded semaglutide for weight loss | Blog Compounded Semaglutide – BloomMD

Open guide Semaglutide Australia Explore Semaglutide research products, GLP-1 pathway listings, vial formats, pricing, and related metabolic products

doi: 10.1039/c2cc34434c

If GLP-1 therapy is initiated , a structured monitoring plan should include: Regular assessment of weight, BMI and nutritional status Monitoring of hydration and renal function, particularly if experiencing significant gastrointestinal symptoms For diabetes patients, appropriate retinopathy surveillance if glycaemic control improves rapidly (especially with semaglutide) [5] [11] Regular review of Crohn's disease activity using clinical and biochemical markers Remember that you are an active participant in your healthcare decisions, and your concerns and experiences should guide the treatment plan

In December 2025, the Food and Drug Administration (FDA) approved an oral pill form of Wegovy for weight loss, and in April 2026 approved the once-daily oral GLP-1 drug Foundayo (orforglipron) also for weight loss

10.1111/jdi.12906 [DOI] [PMC free article] [PubMed] [Google Scholar] 52

This is important because using the same spot over time can cause lipohypertrophy